Often, analysts are responsible for creating reports on companies that are now or could potentially be a client of their employer. The company's stock is moving with the distance from SMA 50 of -1.52 Percent while the distance from 200-day simple moving average for the stock is -6.9 percent. Protalix BioTherapeutics, Inc. has a 52-week low of 0.26 and a 52-week high of 1.51. The company has its outstanding Shares of 124.01 Million. The price to earnings ratio for the company is 2.63 with a beta of 0. Market capitalization is calculated by multiplying a company's shares outstanding by the current market price of one share. JWN stock has a market capitalization of $7.61 Billion. The investment community uses this figure to determine a company's size, as opposed to sales or total asset figures.
Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) traded up 1.67% in the last Trading session and closed at $1.22.
The (Simple Month Average) SMA20 is at 8.69 percent, its SMA50 Value is 44.86% and SMA200 value is reported as 92.1 Percent. The Return on Equity (ROE) and Return on Investment values are 0 percent and 0 percent respectively.
Nordstrom Inc. (NYSE:JWN) declined -0.88% in the last Trading session and closed at $43.92. Considering the earnings reaction history, The Company has topped 58% percentage. Dividends are mostly given in terms of cash payments, property or as shares of stock. The ATR (Average True Range) value is 0.15. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics, Inc. with MarketBeat.com's FREE daily email newsletter. Breaking that down further, it has performed 3.39% for the week, -2.40% for the month, 258.82% over the last quarter, 103.33% for the past half-year and 37.08% for this previous year.
Now 4 brokers are covering Protalix BioTherapeutics, Inc. The share price of the stock surged 1.91% for the year. The stock's price is 3.04 and their relative strength index (RSI) stands at 29.81. The number of times the company missed analysts' estimates is 6. It indicates oversold and overbought price levels for a stock. Many times a conflict of interest arises due to the relationship between company that they work for and the company whose stock they are paid to track.
For the Current Quarter, 23 analyst are projecting the mean EPS to be $0.27/share. 0 said it's a Buy, 0 assigned Hold rating where 0 stated the stock as Underperform and 0 marked the stock as Sell.